TransMedics Group, Inc. (NASDAQ:TMDX) Short Interest Update

TransMedics Group, Inc. (NASDAQ:TMDX) was the recipient of a significant growth in short interest during the month of January. As of January 31st, there was short interest totalling 11,130,000 shares, a growth of 23.8% from the January 15th total of 8,990,000 shares. Based on an average trading volume of 2,000,000 shares, the days-to-cover ratio is currently 5.6 days.

Insider Buying and Selling

In related news, insider Tamer I. Khayal sold 1,084 shares of the business’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $86.40, for a total transaction of $93,657.60. Following the transaction, the insider now directly owns 20,843 shares in the company, valued at approximately $1,800,835.20. The trade was a 4.94 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 7.00% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On TransMedics Group

Hedge funds have recently made changes to their positions in the stock. Clear Creek Financial Management LLC purchased a new position in shares of TransMedics Group during the 4th quarter worth approximately $352,000. Vaughan Nelson Investment Management L.P. lifted its holdings in TransMedics Group by 9.9% during the 4th quarter. Vaughan Nelson Investment Management L.P. now owns 361,615 shares of the company’s stock worth $22,547,000 after buying an additional 32,605 shares in the last quarter. State of Alaska Department of Revenue acquired a new stake in TransMedics Group during the 3rd quarter worth approximately $2,560,000. Charles Schwab Investment Management Inc. lifted its holdings in TransMedics Group by 2.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 271,694 shares of the company’s stock worth $42,656,000 after buying an additional 6,634 shares in the last quarter. Finally, Zacks Investment Management acquired a new stake in TransMedics Group during the 3rd quarter worth approximately $1,607,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Analyst Ratings Changes

TMDX has been the topic of a number of recent research reports. Oppenheimer restated an “outperform” rating and set a $125.00 price target on shares of TransMedics Group in a research report on Tuesday, December 3rd. Piper Sandler decreased their target price on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a report on Wednesday, December 11th. TD Cowen dropped their price target on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a research note on Monday, November 18th. Robert W. Baird dropped their price target on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a research note on Wednesday, December 11th. Finally, Canaccord Genuity Group dropped their price target on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a research note on Wednesday, November 20th. Three analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $122.70.

TransMedics Group Trading Up 1.3 %

Shares of NASDAQ:TMDX traded up $0.96 during mid-day trading on Friday, reaching $72.18. 1,013,799 shares of the company were exchanged, compared to its average volume of 2,287,730. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. The firm has a market cap of $2.42 billion, a price-to-earnings ratio of 76.79 and a beta of 2.12. The firm’s 50-day simple moving average is $65.79 and its 200 day simple moving average is $107.46. TransMedics Group has a 1 year low of $55.00 and a 1 year high of $177.37.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.